A group of researchers in the U.K. has developed a system that uses the principles of grid computing to develop custom reference images for MR brain interpretations. An infoRAD exhibit at the 2003 RSNA meeting explains how age- and gender-specific
A group of researchers in the U.K. has developed a system that uses the principles of grid computing to develop custom reference images for MR brain interpretations.
An infoRAD exhibit at the 2003 RSNA meeting explains how age- and gender-specific images can be drawn from a brain reference atlas to permit automated comparisons that can be used to develop a more accurate diagnosis.
Grid computing links computers in networks to achieve tasks that are processor intensive and otherwise possible only on supercomputers. Although becoming more common in the IT world, it is just beginning to appear in medical applications.
The system developed by the British research team links reference images from 200 brains and allows searches that can be customized. Reference images are averaged and the result used for comparisons that can be tailored to an individual.
In one example, images from a 67-year-old woman with early signs of Alzheimer's disease are compared with data from demographically similar images drawn from the system's brain atlas. The comparison shows that the woman's ventricles are at the 95th percentile in size, an indication that she is edging toward Alzheimer's disease.
The value of grid computing is that image registration can be a computer-intensive process, said research team member Dr. Rolf Heckemann, an informatics expert at the Hammersmith Hospital. Using the power of multiple computers makes possible a quick search for reference images and averaging of their data that can be used for comparisons with the subject's images in a region of interest.
Other registration tasks that might benefit from grid techniques include temporal matching of tissue changes and fusion matching of images. The goal is diagnostic decision support, Heckemann said. Eventually, the system could link distributed data repositories, as additional data help improve the confidence of the diagnosis.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.